Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Expansion Therapeutics | 2023 | Venture - Series Unknown | $6.9M | San Diego |
| Parabilis Medicines | 2026 | Series F | $305.0M | Cambridge |
| Akura Medical | 2025 | Series C | $53.0M | Los Gatos |
| BlossomHill Therapeutics | 2025 | Series B | $84.0M | San Diego |
| Aspen Neuroscience | 2025 | Series C | $115.0M | San Diego |
| Solid Biosciences | 2026 | Post Ipo Equity | $240.0M | Charlestown |
| Candid Therapeutics | 2026 | Undisclosed | $505.0M | San Diego |
| Beam Therapeutics | 2026 | Post Ipo Debt | $100.0M | Cambridge |
| Third Arc Bio | 2026 | Series A | $52.0M | Boston |
| Adlai Nortye | 2026 | Post Ipo Equity | $140.0M | Hangzhou |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 26 | Expansion Therapeutics | Venture - Series Unknown | $6.9M | San Diego, United States |
| 27 | Parabilis Medicines | Series F | $305.0M | Cambridge, United States |
| 28 | Akura Medical | Series C | $53.0M | Los Gatos, United States |
| 29 | BlossomHill Therapeutics | Series B | $84.0M | San Diego, United States |
| 30 | Aspen Neuroscience | Series C | $115.0M | San Diego, United States |
| 31 | Solid Biosciences | Post Ipo Equity | $240.0M | Charlestown, United States |
| 32 | Candid Therapeutics | Undisclosed | $505.0M | San Diego, United States |
| 33 | Beam Therapeutics | Post Ipo Debt | $100.0M | Cambridge, United States |
| 34 | Third Arc Bio | Series A | $52.0M | Boston, United States |
| 35 | Adlai Nortye | Post Ipo Equity | $140.0M | Hangzhou, China |
Expansion Therapeutics is a biotechnology company focusing on developing transformative oral medicines for severe RNA-mediated diseases.
Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.
Akura Medical is developing a next-generation thrombectomy device that aims to simplify thrombectomy through an easy-to-use.
BlossomHill Therapeutics is a biopharmaceutical company focusing on oncology and autoimmune disorders.
Aspen Neuroscience is a biotechnology company that specializes in personalized cell therapies and autologous regenerative medicine.
Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.
Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.
Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases.
Adlai Nortye is a clinical-stage biopharmaceutical company that deveops cancer treatments for diverse tumor types.
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways.
Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.
Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.
Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.
Wave Life Sciences is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling diseases
Tessera Therapeutics is a biotechnology company pioneering Gene Writing™ to drive advancements in genome engineering.
Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening.
Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process.
MoonLake Immunotherapeutics is a clinical-stage biopharmaceuticals company.
X4 Pharmaceuticals is a clinical-stage oncology company developing oral small molecule CXCR4 antagonists for the treatment.
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Electra Therapeutics is a clinical-stage biotechnology company developing antibody therapies for immunological diseases and cancer.
Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies.
Biomea Fusion is a precision oncology company developing novel small molecules that target aggressive forms of cancer.
Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
Cormorant Asset Management has invested in 134 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Cormorant Asset Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 16 different industry categories.
Among tracked funding rounds, Structure Therapeutics received $747.5M in a Post Ipo Equity round. Cormorant Asset Management's total known invested capital is $11.5B.
Cormorant Asset Management's average investment size is $127.4M across its portfolio of 134 companies.
Recent Cormorant Asset Management portfolio additions include Expansion Therapeutics, Parabilis Medicines, Akura Medical, BlossomHill Therapeutics, Aspen Neuroscience. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors